ACLY and neoplasm: Although our data strongly support ACLY as the principal target of EVT0185 in driving tumour immunogenicity, it remains possible that other targets may be important as we found that this compound also reduced acetate incorporation into fatty acids and sterols, an effect that was independent of ACLY.